Molecular modulators of polycystin signaling

多囊蛋白信号传导的分子调节剂

• 批准号: 10356036
• 负责人: STEFAN SOMLO
• 金额: $ 42.4万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10356036
• 关键词: ATAC-seq; Address; Adult; Affect; Affinity Chromatography; Antisense Oligonucleotides; Apoptosis; Attenuated; Autosomal Dominant Polycystic Kidney; Biological Assay; Biology; Cell Culture System; Cell Culture Techniques; Cell Cycle; Cell Line; Cell Proliferation; Cells; ChIP-seq; Chromatin; Chromatin Structure; Cilia; Complex; Consensus; Cyst; Data; Dialysis procedure; Disease; Down-Regulation; GLIS2 gene; Gene Dosage; Genes; Genetic; Genetic Diseases; Genetic Transcription; Genotype; Growth; In Vitro; Inherited; Investigation; Kidney; Kidney Diseases; Knowledge; Maps; Modeling; Molecular; Mutation; Oxidative Phosphorylation; PKD2 protein; Pathogenesis; Pathway interactions; Patients; Polycystic Kidney Diseases; Post-Translational Protein Processing; Pre-Clinical Model; Property; Proteins; Proteolytic Processing; Renal function; Research; Resolution; Ribosomes; Role; Signal Pathway; Signal Transduction; Time; Tissues; Transgenic Organisms; Translating; Transplantation; Transposase; Up-Regulation; Vitelliform macular dystrophy; base; differential expression; dosage; early onset; expectation; field study; human disease; improved; in vitro Model; in vivo; in vivo Model; innovation; mouse model; mutant; novel; novel therapeutics; optimal treatments; overexpression; polycystic liver disease; programs; targeted treatment; therapeutic target; trafficking; transcription factor; transcriptome; transcriptome sequencing; transcriptomics

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease that results from mutations in either of two proteins, polcysytin-1 (PC1) or polycystin-2 (PC2). More than two decades have passed since the genes encoding these proteins were discovered and there has been significant progress in understanding the functions of polycystins and their associated disease. Nonetheless, there remain substantial gaps in knowledge and lack of consensus about the precise functions of PC1 or PC2 and the mechanisms of ADPKD. Resolution of these gaps is of great significance given our expectation that optimal therapies for ADPKD are best developed based on the fundamental understanding of polycystin function in the mammalian kidney. Much of the current mechanistic understanding of polycystin function is based on studies of candidate pathways drawn from amongst known cellular mechanisms associated with functions such as differentiation, proliferation, transport and signaling. The lack of coalescence toward an interrelated unifying functional pathway in polycystin biology and the persistence of gaps in understanding of in vivo polycystin function despite extensive investigation suggests that the critical components of the most proximal polycystin signaling cascade have yet to be identified. Indeed, the polycystins were discovered as complex, entirely novel proteins and it stands to reason that they may function in a signaling pathway that is not among those that are currently well understood or studied. We made use of this concept in by applying an unbiased in vivo transcriptomic study using Translating Ribosome Affinity Purification (TRAP) RNASeq. From this, we identified upregulation of cell cycle and down regulation of oxidative phosphorylation as key pathways alterations in vivo. Among these, we found genotype dependent upregulation of a cilia associated transcription factor, Glis2, not previously considered to function in polycystin signaling or ADPKD pathogenesis. We made double mutants of Pkd1 with Glis2 in early onset and adult models and found Glis2 dosage-dependent rescue of cyst formation in both. Based on these findings we propose that Glis2 is a candidate for a downstream effector of PC1 function that is critical for cyst progression in ADPKD. In this study, we will determine the in vivo mechanism of action of Glis2 and establish its effects on cyst cell proliferation, apoptosis and ADPKD due to Pkd2. We will determine whether Glis2 is a target for therapy through both genetic and pharmacotherapeutic studies. We will assess whether in vivo genotype dependent transcriptional changes we have identified are similarly extended to cell culture systems with Pkd mutant genotypes. We will also evaluate the functional properties of Glis2 protein in Pkd mutant cell lines. In aggregate, these studies open a new direction of investigation for polycystin signaling and ADPKD pathogenesis.

常染色体显性多囊肾病（ADPKD）是一种常见的遗传性疾病，由以下原因引起： 多囊蛋白-1 (PC1) 或多囊蛋白-2 (PC2) 两种蛋白中的任何一个发生突变。二十多年过去了 自从编码这些蛋白质的基因被发现并且在这方面取得了重大进展 了解多囊蛋白的功能及其相关疾病。尽管如此，仍然存在大量 对于 PC1 或 PC2 的确切功能及其机制存在知识差距和缺乏共识 ADPKD。鉴于我们期望 ADPKD 的最佳治疗方法，解决这些差距具有重要意义 最好是基于对哺乳动物肾脏中多囊蛋白功能的基本了解而开发。 目前对多囊蛋白功能的大部分机制理解都是基于对候选途径的研究 取自与分化、增殖等功能相关的已知细胞机制， 传输和信号传输。多囊蛋白中缺乏相互关联的统一功能途径的聚结 尽管进行了广泛的研究，但对体内多囊蛋白功能的理解仍然存在生物学上的差距 表明最近的多囊蛋白信号级联的关键成分尚未确定。 事实上，多囊蛋白被发现是一种复杂的、全新的蛋白质，并且理所当然地，它们 可能在目前尚未充分理解或研究的信号通路中发挥作用。我们 通过使用翻译核糖体进行无偏见的体内转录组学研究，利用了这一概念 亲和纯化 (TRAP) RNASeq。由此，我们确定了细胞周期的上调和细胞周期的下调 氧化磷酸化作为体内关键途径的改变。其中，我们发现基因型依赖性 纤毛相关转录因子 Glis2 的上调，此前不认为该因子在多囊蛋白中发挥作用 信号传导或 ADPKD 发病机制。我们在早发型和成人模型中制作了 Pkd1 和 Glis2 的双突变体 并发现 Glis2 对囊肿形成的拯救作用呈剂量依赖性。根据这些发现，我们建议 Glis2 是 PC1 功能下游效应子的候选者，PC1 功能对于 ADPKD 囊肿进展至关重要。在 在这项研究中，我们将确定 Glis2 的体内作用机制并确定其对囊肿细胞的影响 Pkd2 导致的增殖、凋亡和 ADPKD。我们将通过以下方式确定 Glis2 是否是治疗靶点： 遗传和药物治疗研究。我们将评估体内基因型是否依赖 我们发现的转录变化同样扩展到具有 Pkd 突变体的细胞培养系统 基因型。我们还将评估 Pkd 突变细胞系中 Glis2 蛋白的功能特性。总的来说， 这些研究为多囊蛋白信号传导和 ADPKD 发病机制的研究开辟了新的方向。